This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

About UsOur MissionHistory & MilestonesManagement TeamSupervisory BoardOur Values

About Us

Dedicated to giving cancer patients better answers than "maybe"

ITM Isotopen Technologien München AG is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.

Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of innovative, first-in-class medical radioisotopes and generator platforms for a new generation of targeted cancer diagnostics and therapies.

Furthermore, ITM is developing a proprietary portfolio and growing Precision Oncology Pipeline of targeted treatments in various stages of clinical development. ITM’s lead candidate Solucin®, consisting of the highly pure EndolucinBeta® (no-carrier-added Lutetium-177) and the targeting molecule Edotreotide, is currently undergoing an international phase III clinical trial, known as COMPETE. COMPETE is evaluating efficacy and safety of Targeted Radionuclide Therapy with n.c.a. 177Lu-Edotreotide (Solucin®) compared to standard therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET).

ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

Company Structure ITM Group